BPC-157 vs GHK-Cu: Human Evidence and FDA Status
App Library Tools Pricing Download
[Peptides · Comparison]

BPC-157 vs GHK-Cu: what does the evidence show?

Human evidence · FDA status · Sport

Short answer: Both are unapproved peptides with mostly animal and cell evidence. BPC-157 has 3 small human studies with 30 people in total.1 GHK-Cu is a copper-bound tripeptide found in human plasma;2 its human research is mostly small trials of skin creams, not injections.3 FDA has moved both, GHK-Cu for injection only, to its "nominated but withdrawn" compounding list.4

How do BPC-157 and GHK-Cu compare side by side?

From published studies, FDA compounding pages and the 2026 WADA List. Neither has a US drug label.
BPC-157GHK-Cu
What it isSynthetic 15-amino-acid peptide based on a gastric protein fragmentCopper complex of the tripeptide glycyl-histidyl-lysine, present in human plasma, saliva and urine2
Approval statusNot FDA approvedNot FDA approved as a drug; used in cosmetic products2
Human studies3 small uncontrolled studies, 30 people in total1Mostly small trials of facial cosmetic creams3
Main human routeInjection (knee, bladder wall, IV)1On the skin3
Example resultPilot studies without control groups; very low certainty1After laser resurfacing (13 patients): no objective difference vs regimen without GHK-Cu5
Half-lifeUnder 30 minutes in rats and dogs; no human value6No published human value
FDA compounding statusNominated but withdrawn4Nominated but withdrawn, for injectable routes4
FDA advisory committee 2026Reviewed July 2026 (ulcerative colitis use)7Not on the July 2026 agenda7
SportWADA S0, named8Not named on the 2026 List8

Reviewed . Half-life figures are shown only where the value Dose Track uses agrees with the cited source.

What human evidence exists for GHK-Cu?

GHK is present in human plasma, saliva and urine, and its levels fall with age.2 Most of the research is in cells and animals. A 2026 systematic review called the human literature "thin and fragmented": most randomized trials are small and test facial cosmetic creams.3 The same review notes that about 35% of the primary GHK-Cu literature includes one research group with long-standing commercial interests in the field.3 In one controlled study after CO2 laser resurfacing (13 patients), skin products with GHK-Cu did not improve redness, wrinkles or skin quality on objective measures, though patients rated their skin better.5 We found no published human trials of injected GHK-Cu.

What human evidence exists for BPC-157?

A 2026 systematic review found 3 human studies with 30 people: a knee pain chart review, a 12-person bladder pilot and a 2-person IV safety pilot, none with a control group, and rated certainty very low.1 A 2025 scoping review called human data "extremely limited."9 More detail is in BPC-157 vs TB-500: what does the evidence actually show?.

What has FDA said?

Both were on FDA's Category 2 compounding list and are now on its "nominated but withdrawn" list, because the nominators withdrew them. For injected GHK-Cu, FDA cites immunogenicity risk from aggregation and impurities and limited human data. For BPC-157, it cites immunogenicity risk and little safety information.4 FDA's advisory committee discussed BPC-157 in July 2026; its vote is non-binding.7

This page summarizes labels and published studies. It is not personalized medical advice; confirm any dose or change with your prescriber.
BPC-157 vs TB-500: what does the evidence actually show?Mostly preclinical evidence, 2026 FDA status TB-500 vs thymosin alpha-1: how do they differ?Same "thymosin" name, different molecules AOD-9604 vs HGH fragment 176-191: are they the same?Two names for nearly the same fragment

Frequently asked questions

Is there human evidence for injected GHK-Cu?+
We found none published. Human GHK-Cu research is mostly small trials of topical skin products, according to a 2026 systematic review.3
Is GHK-Cu FDA approved?+
No. It is used in cosmetics, and FDA lists injectable GHK-Cu among compounding substances that were in Category 2 and then withdrawn by the nominators.4
How much human data is there for BPC-157?+
Three small uncontrolled studies with 30 people in total, rated very low certainty in a 2026 systematic review.1
Are they banned in sport?+
BPC-157 is named under S0 (non-approved substances) on the 2026 WADA List. GHK-Cu is not named on that list.8
Can I track BPC-157 and GHK-Cu in Dose Track?+
Yes. Both are built in, with reconstitution math so each amount shows in syringe units, and reminders.

Sources

  1. Poolton et al. BPC-157 systematic review (PRISMA, PROSPERO-registered). Acta Orthop Belg. 2026.
  2. Pickart L, et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108.
  3. Najafi N, et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Arch Intern Med Res. 2026;9:269-293.
  4. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 and nominated-but-withdrawn lists). Updated April 2026.
  5. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8:252-9.
  6. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022.
  7. FDA. Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026.
  8. World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026 (English text as published in the Dutch Treaty Series, Tractatenblad 2026, 25).
  9. McGuire et al. BPC-157 in musculoskeletal medicine: a scoping review. Curr Rev Musculoskelet Med. 2025.

All compound comparisons · BPC-157 guide · GHK-Cu guide · All compound guides